Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Exercise Therapy for Asthma (ETA Trial) (ETA)

This study has been terminated.
(Study proved difficult to recruit)
Information provided by:
Ohio State University Identifier:
First received: February 6, 2009
Last updated: May 26, 2010
Last verified: May 2010
The purpose of the study is to determine if a program of regular exercise can help reduce asthma symptoms and also reduce the inflammation caused by asthma. If successful, this would allow regular exercise to be recommended as a therapy for people with asthma, which could possibly reduce the amount of medicine that people with asthma need to control their asthma symptoms.


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Exercise Therapy for Asthma (ETA Trial)

Resource links provided by NLM:

Further study details as provided by Ohio State University:

Primary Outcome Measures:
  • To determine the effectiveness of a behavioral intervention, exercise therapy as a primary therapy for asthma [ Time Frame: end of study ]

Secondary Outcome Measures:
  • to determine how one program of exercise therapy affects asthma symptoms and inflammatory markers from the blood and the lung of asthmatics [ Time Frame: end of study ]

Biospecimen Retention:   Samples With DNA

Enrollment: 13
Study Start Date: December 2003
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
no exercise program group
group will continue with current level of activity and will be asked not to start an exercise program. They will be seen in the clinic three times a week for 12 weeks. These visits will be very brief; blood pressure, heart rate, oxygen level and peak flow will be measured at each visit
exercise group
will meet three times a week for 12 weeks, following specific exercise program

Detailed Description:

This is a randomized, controlled, parallel-design study of the effectiveness of exercise therapy as add-on therapy in the treatment of mild to moderately severe asthma.

105 men and women between the ages of 18-50 years with asthma will be randomly assigned to one of two treatment groups: exercise therapy or control. The exercise therapy protocol is detailed below. The control group will receive usual asthma care. The control group will be instructed to maintain their current sedentary activity level, i.e. not to begin a formal or informal exercise program. In order to standardize contact with study personnel between the two groups the control group will be seen three times a week for clinic visits (exercise group will have sessions three times a week). The primary outcome measures are asthma control (asthma symptom score) and asthma-related inflammation. Secondary outcomes include exacerbation rate, asthma-related quality of life, generic quality of life, lung function, airways hyper-reactivity, and cardiovascular fitness. The effect of exercise therapy on inflammatory markers in blood, and sputum will be assessed by comparing results obtained at study completion versus those obtained at baseline.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care clinic, community sample

Inclusion Criteria:

  • • 18-50 years old

    • 50 + years old with prior approval to begin an exercise program from primary care physician within 6 months of enrollment
    • Men and women


  • Doctor diagnosed asthma
  • Lung function tests must meet certain levels common in asthma patients
  • Active, daily doctor-prescribed asthma controller medication (inhaled corticosteroid) for 2 months or longer at a minimum dose equivalent to fluticasone 88 mcg/day, about two (2) puffs. (you can be on other drugs as long as they are in the same dose range as fluticasone)
  • Poor asthma control: Any one of the following conditions:

    • Use of beta-agonist (A bronchodilator medicine that opens the airways by relaxing the muscles around the airways that may tighten during an asthma attack )for asthma symptoms twice/week or more OR
    • Awakening from sleep with asthma symptoms more than once per week OR
    • One or more control problems identified on the Asthma Treatment and Control Questionnaire (ATAQ).

Smoking status:

  • Non-smoker for 6 months or longer
  • Less than 10 pack year (number of packs per day (x) years of smoking = pack years) smoking history

Exclusion Criteria:

  • • Poor lung function

    • Current participation in a regular aerobic exercise program (formal or at home)
    • Any "yes" to any one of items a-e of question number two of the Stanford Usual Activity Questionnaire
    • Pregnancy
    • Sudden illness that accompanies fever (> 38.00 C or 100.40F) within 24 hours of Visit 2
    • Participation in another interventional research trial Other major chronic illnesses that would interfere with participation in the study

Medication use:

  • Chronic oral corticosteroid use
  • Oral corticosteroid use within 4 weeks of study start
  • Anti-coagulants (An anticoagulant is a drug that helps prevent the clotting (coagulation) of blood.), insulin, any investigative drugs within 2 months

Drug allergy:

• Previous adverse effects from methacholine challenge


  • Inability or unwillingness to provide consent
  • Inability to perform aerobic exercise
  • Inability to perform baseline measurements
  • Less than 80% completion of screening period diaries
  • Inability to contact by telephone
  • Intention to move out of the area within 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00839137

United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Ohio State University
Principal Investigator: John G Mastronarde, MD Ohio State University
  More Information

Responsible Party: John G. Mastronarde, MD, The Ohio State University Identifier: NCT00839137     History of Changes
Other Study ID Numbers: 2003H0213
Study First Received: February 6, 2009
Last Updated: May 26, 2010

Keywords provided by Ohio State University:
exercise therapy

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on April 21, 2017